TP53 and neoplasm: Moreover, IR/CCR5i/αPD1-treated tumor sections had significantly reduced DAPI+ and p53+ KPC cells compared to all other conditions, suggesting significantly more loss of tumor cells by triple combination treatment (Figure 3B, Figure 3—figure supplement 1B and C).